Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

• Status: Terminated
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2).

This study is designed to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of PTK787 when administered in combination with Pemetrexed or Pemetrexed and Cisplatin, and to characterize the safety, tolerability, biologic activity, and PK profile of PTK787 in adult patients with advanced non-small cell lung cancers and mesotheliomas.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nevada Cancer Institute
• Treatments: Cisplatin; Pemetrexed; Vatalanib

Criteria

Inclusion Criteria:

• Patients with advanced non-small cell lung cancers (non-squamous variety and advanced mesotheliomas

• Patients with advanced solid tumors who are refractory to standard treatments and/or standard treatments are not be available for the patient

Exclusion Criteria:

• Non-small cell carcinoma of squamous variety

• Patients with uncontrolled brain metastases